Press Room

Webinar - Accessing Continuous Tableting Through a CDMO

Start
Wednesday, October 11, 2023 - 16:00
Location: online

October 11, 2023

11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

 

Available on-demand

 

Featured Hovione experts in this webinar
Hovione_Sarang Oka
Sarang Oka

Production Senior Manager

Drug Product Continuous Manufacturing

 

The webinar, focused on Continuous Tableting of oral solid dosage forms, also known as Continuous Tableting (CT), will introduce the concept of working with a CDMO to develop and launch a CT-based program. The discussion will focus on the business case for Continuous Tableting in the context of working with a CDMO.

 

Intrinsic technology-driven advantages such as higher product quality, greater supply chain flexibility, opportunity to accelerate time-to-market and ability to implement advanced process control as well as those that manifest from working with an experienced CDMO will be shared.

 

Key Learning Objectives: 

  • Learn about important considerations when implementing Continuous Tableting – advantages and challenges.
  • Understand the advantages of working with a CDMO for a Continuous Tableting based program. This includes new products as well as batch to continuous conversions.
  • Case studies will be presented showing how big data sets generated in Continuous Tableting enable the implementation of process improvements.

Who Should Attend

  • Individuals and organizations who are curious to learn about technology, its fundamental benefits and challenges.
  • Current and aspiring practitioners of the technology who are interested about the implementation of Continuous Tableting at a CDMO.

 

Available on-demand

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026